Cary P. Gross, MD, of Yale School of Medicine, discusses the challenges of implementing pathways and guiding patient decision-making on treatment.
Nadine Housri, MD, of the Yale School of Medicine, talks about a new paradigm in sharing knowledge from tumor board discussions at NCI-designated comprehensive cancer centers, with community oncologists on themednet.org. Currently, thoracic, breast, and GI cancers are included, with plans to expand the scope (Abstract 272).
Bernardo H. L. Goulart, MD, of Seattle Cancer Care Alliance, discusses his findings that high out-of-pocket costs for oral tyrosine kinase inhibitors may lower survival rates, shorten the duration of therapy, and reduce the number of prescriptions for patients with metastatic EGFR- or ALK-positive non–small cell lung cancer (Abstract 3).
Grace C. Hillyer, EdD, MPH, of Columbia University Mailman School of Public Health, discusses the many barriers to enrolling patients in clinical trials, most notably different attitudes toward and perceptions about research studies among clinicians vs patients. Her findings point to the need for better communication between the two groups and more patient input (Abstract 170).
Elena Martinez, PhD, MPH, of Moores Cancer Center at the University of California, San Diego, discusses the challenges of ensuring diversity in precision oncology and potential solutions to address the challenges.
Michael Kenneth Keng, MD, of the University of Virginia, gives a status update on this international program, and discusses future initiatives which include coaching mentorship and publishing articles on quality care (Abstract 7).
